A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)

NCT02381496 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: ACT-453859 1 mg
DRUG: ACT-453859 3 mg
DRUG: ACT-453859 10 mg
DRUG: ACT-453859 30mg
DRUG: ACT-453859 100 mg
DRUG: ACT-453859 300 mg
DRUG: ACT-453859 800 mg
OTHER: Placebo
DRUG: Setipiprant 500 mg
DRUG: Setipiprant 1000 mg

Sponsor

Idorsia Pharmaceuticals Ltd.